ZenTech, DIAsource ImmunoAssays ink milestone agreement
ZenTech, a Belgian biotech company specialized in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening, and DIAsource ImmunoAssays, a leading diagnostics company delivering manual RIA and ELISA kits and open automation solutions to international markets, have announced a strategic agreement, under which ZenTech will transfer its portfolio of RIA products to DIAsource, securing the continued production and sales of these products. ZenTech has strategically reoriented itself to focus on newborn screening and early life stage diseases. DIAsource is the second largest supplier of radioimmuno as says in the world, committed to servicing customers worldwide that use manual ELISA and RIA assays and open automation to complement their portfolio on closed automated systems. ZenTech has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity. The company exports more than 95 per cent of its production, especially to Middle East and South East Asia, China, South America and Africa.